Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Estes C, et al. Among authors: bellentani s. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156 Free article.
From NAFLD in clinical practice to answers from guidelines.
Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. Nascimbeni F, et al. Among authors: bellentani s. J Hepatol. 2013 Oct;59(4):859-71. doi: 10.1016/j.jhep.2013.05.044. Epub 2013 Jun 7. J Hepatol. 2013. PMID: 23751754 Free article. Review.
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group. Munteanu M, et al. Among authors: bellentani s. Aliment Pharmacol Ther. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770. Epub 2016 Aug 23. Aliment Pharmacol Ther. 2016. PMID: 27549244 Free PMC article.
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
Non-alcoholic Fatty Liver Disease Study Group; Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Non-alcoholic Fatty Liver Disease Study Group, et al. Among authors: bellentani s. Dig Liver Dis. 2015 Dec;47(12):997-1006. doi: 10.1016/j.dld.2015.08.004. Epub 2015 Aug 14. Dig Liver Dis. 2015. PMID: 26454786 Review.
Is it time to change NAFLD and NASH nomenclature?
Bellentani S, Tiribelli C. Bellentani S, et al. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):547-548. doi: 10.1016/S2468-1253(17)30146-2. Lancet Gastroenterol Hepatol. 2017. PMID: 28691681 No abstract available.
104 results